Want to join the conversation?
Biotechnology company $VRTX said that Health Canada has approved PrORKAMBI for treatment of the underlying cause of cystic fibrosis in people aged 12 and older. The approval was based on data from two Phase 3 studies (TRAFFIC and TRANSPORT) that enrolled 1,100 plus people with CF aged 12 and older.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.